Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus Paclitaxel-Carboplatin in First-Line Squamous NSCLC
NCT01769391Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of necitumumab in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Started Jan 2013; status: completed.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01769391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769391.